Elanco Animal Health Inc
No SEC Form 4 filings for $ELAN in the last 30 days.
Elanco Animal Health (NYSE:ELAN) reported adjusted earnings of 34 cents per share, above the 27-cent consensus. Q2 sales rose 10% to $1.368B. Pet Health revenue grew 12% to $718M. The company raised FY2026 guidance: adjusted EPS to $1.10-$1.16 and sales to $5.09-$5.14B.
S&P 500 futures rose about 0.4% to near 7,800, a new all-time high, after strong earnings and record S&P 500 call buying. Nasdaq-100 futures lagged as AMD and SpaceX results disappointed. Nvidia gained on an exclusive partnership to build AI infrastructure on NVIDIA platforms. Several other stocks moved on guidance or earnings, including ANET, SHOP, CVS, and FLUT.
Elanco Animal Health (ELAN) reported Q2 results and issued Q3 guidance, expecting adjusted EPS of $0.19 to $0.22 on revenue of $1.195B to $1.220B, with 5% to 7% organic constant-currency growth. For FY2026, it raised outlook to adjusted EPS $1.10 to $1.16 on revenue $5.09B to $5.14B, up from prior $1.03 to $1.09 on $5.01B to $5.085B. Shares rose to $27.37.
Over the past 7 days, alphai's AI scored 9 news stories mentioning ELAN (Elanco Animal Health Inc). Coverage has skewed bullish: 7 bullish, 2 neutral, and 0 bearish.
Recent ELAN coverage spans earnings, market movers and financial news.
Guidance upside plus margin and leverage progress suggests improving fundamentals, supporting near-term momentum and reducing downside risk versus prior expectations.
Guidance upgrade supports near-term sentiment and potential estimate revisions.
Guidance raise signals improving demand and margin outlook, likely supporting near-term sentiment and positioning for FY26 estimates.
Earnings beat plus raised outlook and faster leverage reduction are likely to sustain upside momentum after the pre-open surge.
Beat-and-better guidance likely supports near-term upside, but margin contraction and slower forward growth temper the rally.
alphai scores every news story that mentions ELAN with an AI model for sentiment and relevance, and aggregates insider trades from Elanco Animal Health Inc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Elanco Animal Health (NYSE:ELAN) reported adjusted earnings of 34 cents per share, above the 27-cent consensus. Q2 sales rose 10% to $1.368B. Pet Health revenue grew 12% to $718M. The company raised FY2026 guidance: adjusted EPS to $1.10-$1.16 and sales to $5.09-$5.14B.
6 min readS&P 500 futures rose about 0.4% to near 7,800, a new all-time high, after strong earnings and record S&P 500 call buying. Nasdaq-100 futures lagged as AMD and SpaceX results disappointed. Nvidia gained on an exclusive partnership to build AI infrastructure on NVIDIA platforms. Several other stocks moved on guidance or earnings, including ANET, SHOP, CVS, and FLUT.
7 min readElanco Animal Health (ELAN) reported Q2 results and issued Q3 guidance, expecting adjusted EPS of $0.19 to $0.22 on revenue of $1.195B to $1.220B, with 5% to 7% organic constant-currency growth. For FY2026, it raised outlook to adjusted EPS $1.10 to $1.16 on revenue $5.09B to $5.14B, up from prior $1.03 to $1.09 on $5.01B to $5.085B. Shares rose to $27.37.
2 min readElanco Animal Health (ELAN) rose about 8.9% in pre-open after reporting Q2 2026 results ahead of estimates. Adjusted EPS was $0.34 vs $0.27 consensus, and revenue was $1.37B vs $1.31B, with organic constant-currency growth of 8%. Adjusted EBITDA was $288M, net leverage improved to 3.1x, and full-year guidance was lifted, pushing the stock to a new 52-week high.
3 min readElanco (NYSE:ELAN) reported Q2 CY2026 revenue of $1.37 billion, up 10.2% year on year and 4.2% above Wall Street estimates, according to the company. Non-GAAP EPS was $0.34, 26.5% above consensus. Next-quarter revenue guidance was $1.21 billion at the midpoint. The article also notes a stock rise to $27.16.
4 min readElanco Animal Health (NYSE: ELAN) reported Q2 2026 revenue of $1.368B, up 10% year over year (8% organic constant currency). Adjusted EPS was $0.34 and adjusted EBITDA $288M (21.2% margin). It raised full-year 2026 guidance, including revenue to $5.09B-$5.14B and adjusted EBITDA to $1.01B-$1.035B, and targeted year-end net leverage of about 3.0x.
6 min readElanco Animal Health Inc (ELAN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 elanco-20260630exhibit991.htm EXHIBIT 99.1 - PRESS RELEASE DATED AUGUST 5, 2026 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Investor Contact: Tiffany Kanaga (765) 740-0314 or tiffany.kanaga@elancoah.com Media Contact: Colleen Parr Dekker (317) 989-7011 or colleen.dekker
6 min readElanco (NYSE: ELAN) is set to report Q2 results Wednesday before market open. The company previously beat revenue expectations with $1.37B revenue, up 14.9% year on year, and beat EPS estimates, though EBITDA guidance missed. Ahead of earnings, analysts expect revenue up 5.8% y/y, with an average price target of $30.07 vs $25.71.
4 min readElanco Animal Health (NYSE:ELAN) released its 2025 Impact Report, “Leading with Purpose,” outlining progress across animals, customers, society and people. The company said 2025 revenue from new innovation was $892 million, including products such as Credelio Quattro and Zenrelia, and cited initiatives like a Salmonella program in 23 countries and 250 Indianapolis families aided by Nutrition Secure Indy.
3 min readBank of America reiterated a Buy rating on Elanco Animal Health (NYSE:ELAN) and named it its top pick in animal health, citing a clearer catalyst profile and potential upside to earnings estimates. The bank kept IDEXX Laboratories (NASDAQ:IDXX) at Neutral, saying near-term visit pressure is largely priced in. IDEXX reported Q1 2026 revenue of $1.14B and EPS of $3.47.
2 min read
